Urotensin II: A new pharmacologic target in the treatment of cardiovascular disease

Cardiology in Review

Volumn 16, Issue 3, 2008, Pages 142-153

  Desai, Nirav ^a   Sajjad, Jameel ^b   Frishman, William H ^c,d  

^a UCLA MEDICAL CENTER   (United States)

^b St Barnabas Medical Center   (United States)

^c WESTCHESTER MEDICAL CENTER   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Urotensin II; Urotensin II receptor blockers

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACT 058362; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PALOSURAN; PROTEIN KINASE C INHIBITOR; RECEPTOR BLOCKING AGENT; SB 611812; UFP 803; UNCLASSIFIED DRUG; UROTENSIN II;

ATHEROSCLEROSIS; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DRUG TARGETING; HEART ARRHYTHMIA; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HYPERTENSION; KIDNEY DISEASE; LUNG EDEMA; MONKEY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN STRUCTURE; PULMONARY HYPERTENSION; RAT; RECEPTOR BLOCKING; REVIEW; STREPTOZOCIN DIABETES; TISSUE DISTRIBUTION; VASOCONSTRICTION;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; MYOCARDIAL CONTRACTION; QUINOLINES; RECEPTORS, G-PROTEIN-COUPLED; SULFONAMIDES; UREA; UROTENSINS; VASOCONSTRICTOR AGENTS;

EID: 42249094694     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e31815c8048     Document Type: Review

References (89)

1. Bern HA, Pearson D, Larson BA, et al. Neurohormones from fish tails: the caudal neurosecretory system. I. "Urophysiology" and the caudal neurosecretory system in fishes. Recent Prog Horm Res. 1985;41:533-552.
2. Pearson D, Shively JE, Clark BR, et al. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA. 1980;77:5021-5024.
3. Conlon JM, O'Harte F, Smith DD, et al. Isolation and primary structure of urotensin II from the brain of a tetrapod, the frog Rana ridibunda. Biochem Biophys Res Commun. 1992;188:578-583.
4. Coulouarn Y, Lihrmann I, Jegou S, et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA. 1998;95:15803-15808.
5. Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401:282-286.
6. Davenport AP, Maguire JJ. Urotensin II: fish neuropeptide catches orphan receptor. Trends Pharmacol Sci. 2000;21:80-82.
7. Conlon JM, Tostivint H, Vaudry H, et al. Somatostatin- and urotensin II-related peptides: molecular diversity and evolutionary perspectives. Regul Pept. 1997;69:95-101.
8. Ohsako S, Ishida I, Ichikawa T, et al. Cloning and sequence analysis of cDNAs encoding precursors of urotensin II-alpha and -gamma. J Neurosci. 1986;6:2730-2732.
9. Shenouda A, Douglas SA, Ohlstein EH, et al. Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J Histochem Cytochem. 2002;50:885-889.
10. Silvestre RA, Egido EM, Hernandez R, et al. Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. Eur J Endocrinol. 2004;151:803-809.
11. Zhu Y, Zhu Y, Moore PK, et al. The role of urotensin II in cardiovascular and renal physiology and diseases. Br J Pharmacol. 2006;148:884-901.
12. Conlon JM, Yano K, Waugh D, et al. Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. J Exp Zool. 1996;275:226-238.
13. Itoh H, McMaster D, Lederis K, et al. Functional receptors for fish neuropeptide urotensin II in major rat arteries. Eur J Pharmacol. 1988;149:61-66.
14. Protopopov A, Kashuba V, Podowski R, et al. Assignment of GPR14 gene coding for the G-protein-coupled receptor 14 to human chromosome 17q25.3 by fluorescent in situ hybridization. Cytogenet Cell Genet. 2000;88:312-313.
15. Marchese A, Heiber M, Nguyen T, et al. Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8 neuropeptide Y, and somatostatin receptors. Genomics. 1995;29:335-344.
16. Matsushita M, Shichiri M, Imai T, et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens. 2001;19:2185-2190.
17. Maguire JJ, Kuc RE, Wiley KE, et al. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides. 2004;25:1767-1774.
18. Liu Q, Pong SS, Zeng Z, et al. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun. 1999;266:174-178.
19. Maguire JJ, Kuc RE, Davenport AP, et al. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol. 2000;131:441-446.
20. Opgaard OS, Nothacker HP, Ehlert FJ, et al. Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol 2000;406:265-271.
21. Onan D, Pipolo L, Yang E, et al. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol. 2004;18:2344-2354.
22. Lin Y, Matsumura K, Tsuchihashi T, et al. Role of ERK and Rho kinase pathways in central pressor action of urotensin II. J Hypertens. 2004;22:983-988.
23. Nothacker HP, Clark S. From heart to mind. The urotensin II system and its evolving neurophysiological role. FEBS J. 2005;272:5694-5702.
24. Tzanidis A, Hannan RD, Thomas WG, et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res. 2003;93:246-253.
25. Russell F. Emerging roles of urotensin-II in cardiovascular disease. Pharmacol Ther. 2004;103:223-243.
26. Chien KR, ed. Molecular Basis of Cardiovascular Disease. 2nd ed. Philadelphia, PA: Saunders; 2004.
27. Yamazaki T, Komuro I, Yazaki Y, et al. Signaling pathways for cardiac hypertrophy. Cell Signal. 1998;10:693-698.
28. Zou Y, Nagai R, Yamazaki T. Urotensin II induces hypertrophy responses in cultured cardiomyocytes from neonatal rats. FEBS Lett. 2001;508:57-60.
29. Shi L, Ding W, Li D, et al. Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis. 2006;188:260-264.
30. Johns D, Ao Z, Naselsky C, et al. Urotensin-II mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:238-250.
31. Sano M, Fukuda K, Kodama H, et al. Interleukin-6 family of cytokines mediated angiotensin-II induced cardiac hypertrophy in rodents cardiomyocytes. J Biol Chem. 2000;275:29717-29723.
32. Douglas SA, Sulpizio AC, Piercy V, et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol. 2000;131:1262-1274.
33. Paysant J, Rupin A, Simonet S, et al. Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin-II. Fundam Clin Pharmacol. 2001;15:227-231.
34. Hillier C, Berry C, Petrie MC, et al. Effects of urotensin II in human arteries and veins of varying caliber. Circulation. 2001;13:1378-1381.
35. Stirrat A, Gallagher M, Douglas SA, et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol. 2001;280:925-928.
36. Maclean MR, Alexander D, Stirrat A, et al. Contractile response to human urotensin-II in rat and human pulmonary arteries: effect of chronic hypoxia in the rat. Br J Pharmacol. 2000;130:201-204.
37. Bennett RT, Jones RD, Morice AH, et al. Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries. Thorax. 2004;59:401-407.
38. Bottrill FE, Douglas SA, Hiley CR, et al. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol. 2000;130:1865-1870.
39. Lin Y, Tsuchihashi T, Matsumura K, et al. Central cardiovascular action of urotensin II in conscious rats. J Hypertens. 2003;21:159-165.
40. Lu Y, Zou CJ, Huang DW, et al. Cardiovascular effects of urotensin II in different brain areas. Peptides. 2002;23:1631-1635.
41. Gardiner SM, March JE, Kemp PA, et al. Bolus injection of human urotensin-II in conscious rats evokes a biphasic haemodynamic response. Br J Pharmacol. 2004;143:422-430.
42. Gardiner SM, March JE, Kemp PA, et al. Depressor and regionally selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol. 2001;132:1625-1629.
43. Affolter JT, Newby DE, Wilkinson IB, et al. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol. 2002;54:617-621.
44. Lim M, Honisett S, Sparkes CD, et al. Differential effects of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation. 2004;109:1212-1214.
45. Sondermeijer B, Komp A, Komesaroff P, et al. Effects of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens. 2005;18:1195-1199.
46. Cheung BM, Leung R, Man YB, et al. Plasma concentration of urotensin II is raised in hypertension. J Hypertens. 2004;22:1341-1344.
47. Thompson JP, Watt P, Sanghavi S, et al. A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anesth Analg. 2003;97:1501-1503.
48. Russell FD, Molenaar P, O'Brien DM, et al. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol. 2001;132:5-9.
49. Gong H, Wang Y, Zhu Y, et al. Cellular distribution of UT Receptor and the positive inotropic role of urotensin II in the myocardium in adult rat. J Appl Physiol. 2004;97:2228-2235.
50. Hassan GS, Chouiali F, Saito T, et al. Effect of human urotensin-II infusion on hemodynamics and cardiac function. Can J Physiol Pharmacol. 2003;81:125-128.
51. Zhu YZ, Wang ZJ, Zhu YC, et al. Urotensin II causes fatal circulatory collapse in anesthetized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile. Am J Physiol Heart Circ Physiol. 2004;286:830-836.
52. Kompa AR, Thomas WG, See F, et al. Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides. 2004;10:1783-1788.
53. Watson AMD, Lambert GW, Smith KJ, et al. Urotensin-II acts centrally to increase epinephrine and ACTH release and causes potent inotropic and chronotropic actions. Hypertension. 2003;42:373-379.
54. Suguro T, Watanabe T, Ban Y, et al. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens. 2007;20:211-217.
55. Bousette N, Patel L, Douglas SA, et al. Increased expression of urotensin II and its cognate receptor UT receptor in atherosclerotic lesions of the human aorta. Atherosclerosis. 2004;176:117-123.
56. Watanabe T, Pakal R, Katagiri T, et al. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation. 2001;104:16-18.
57. Watanabe T, Pakala R, Katagiri T, et al. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens. 2001;19:2191-2196.
58. Watanabe T, Suguro T, Kanome T, et al. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension. 2005;46:738-744.
59. Joyal D, Huynh T, Aiyar N, et al. Urotensin II levels in acute coronary syndromes. Int J Cardiol. 2006;108:31-35.
60. Ng LL, Loke I, O'Brien RJ, et al. Plasma urotensin in human systolic heart failure. Circulation. 2002;106:2877-2880.
61. Richards AM, Nicholls MG, Lainchbury JG, et al. Plasma urotensin II in heart failure. Lancet. 2002;360:545-546.
62. Russell FD, Meyers D, Galbraith AJ, et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol. 2003;285:1576-1581.
63. Lapp H, Boerrigter G, Costello-Boerrigter LC, et al. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol. 2004;94:93-97.
64. Gruson D, Rousseau MF, Ahn SA, et al. Circulating urotensin II in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides. 2006;6:1527-1531.
65. Douglas SA, Tayara L, Ohlstein EH, et al. Congestive heart failure and expression of myocardial urotensin II. Lancet. 2003;359:1990-1997.
66. Thanassoulis G, Huyhn T, Giaid A, et al. Urotensin II and cardiovascular diseases. Peptides. 2004;25:1789-1794.
67. Ovcharenko E, Abassi Z, Rubinstein I, et al. Renal effects of human urotensin-II in rats with experimental congestive heart failure. Nephrol Dial Transplant. 2006;5:1205-1211.
68. Burrell KM, Molenaar P, Dawson PJ, et al. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. J Pharmacol Exp Ther. 2000;292:449-459.
69. Zhang Y, Li J, Cao J, et al. Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium. Heart Vessels. 2002;16:64-68.
70. Qi J, Du J, Tang X, et al. The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting. Heart Vessels. 2004;19:81-88.
71. Sun DJ, Yang JP, Sun YH, et al. The expression and significance of urotensin II, nitric oxide and C-Type natriuretic peptide in hypoxia-induced pulmonary hypertension in rats. Zhonghua Jie He He Hu Xi Za Zhi. 2006;4:185-192.
72. Djordjevic T, BelAriba RS, Bonello S, et al. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol. 2005;3:519-525.
73. Charles CJ, Rademaker MT, Richards AM, et al. Urotensin II: evidence for cardiac, hepatic and renal production. Peptides. 2005;26:2211-2214.
74. Song W, Abdel-Razik AE, Lu W, et al. Urotensin II and renal function in the rat. Kidney Int. 2006;69:1360-1368.
75. Ashton N. Renal and vascular actions of urotensin II. Kidney Int. 2006;70:624-629.
76. Zhang AY, Chen YF, Zhang DX, et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol. 2003;285:792-798.
77. Douglas SA, Dhanak D, Johns DG, et al. From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci. 2004;25:76-85.
78. Totsune K, Takahashi K, Arihara Z, et al. Role of urotensin II in patients on dialysis. Lancet. 2001;358:810-811.
79. Totsune K, Takahashi K, Arihara Z, et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides. 2004;25:1809-1814.
80. Balat O, Aksoy F, Kutlar I, et al. Increased plasma levels of urotensin-II in preeclampsia-eclampsia: a new mediator in pathogenesis? Eur J Obstet Gynecol Reprod Biol. 2005;120:33-38.
81. Silvestre RA, Rodriguez-Gallardo J, Egido EM, et al. Inhibition of insulin release by urotensin II-a study on the perfused rat pancreas. Horm Metab Res. 2001;33:379-381.
82. Totsune K, Takahashi K, Arihara Z, et al. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (London). 2003;104:1-5.
83. Langham RG, Kelly DJ, Gow RM, et al. Increased expression of urotensin II and urotensin II receptors in human diabetic nephropathy. Am J Kidney Dis. 2004;44:826-831.
84. Clozel M, Hess P, Qiu C, et al. The urotensin II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther. 2006;6:1115-1121.
85. Rakowski E, Hassan GS, Dhanak D, et al. A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J Mol Cell Cardiol. 2005;39:785-791.
86. Bousette N, Hu F, Ohlstein EH, et al. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol. 2006;41:285-295.
87. Pataccini R, Santicioli P, Giuliani S, et al. Urantide: an ultrapotent urotensin II antagonist peptide in rat aorta. Br J Pharmacol. 2003;140:1155-1158.
88. Camarda V, Song W, Marzola E, et al. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol. 2004;498:83-86.
89. Camarda V, Spagnol M, Song W, et al. In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Phe5,DTrp7,Dab8] urotensin II(4-11) (UFP-803). Br J Pharmacol. 2006;147:92-100.